Food Oral Immunotherapy (OIT) Program

Food oral immunotherapy, or OIT, uses carefully measured amounts of a confirmed food allergen to raise the reaction threshold while treatment continues. It is a structured program with supervised escalation, daily home dosing, cofactor precautions, emergency readiness, and long-term follow-up.

Clinic Information

Food Oral Immunotherapy (OIT) Program | Modena Health

Treatment Goals and Evidence

OIT goals, benefits, and expected results

What OIT can—and cannot—do

For some children with an IgE-mediated food allergy, oral immunotherapy may increase the reaction threshold while treatment continues. This can provide a margin of protection against some accidental exposures. Results differ by patient, allergen, age, protocol, and adherence.

OIT does not make an allergen unrestricted, eliminate anaphylaxis risk, or replace label reading, avoidance, epinephrine, or emergency planning. The decision to start should follow confirmation of the allergy and a detailed discussion of benefits, risks, alternatives, and the daily commitment involved.

Potential benefits

The principal potential benefit is a higher reaction threshold while treatment continues. For some families, that may reduce anxiety about small accidental exposures and make school, travel, and social activities easier to plan.

Benefit is not guaranteed. Reactions can still occur, and OIT does not prove that a patient can freely eat the allergen or that hospitalization or anaphylaxis cannot happen. Individual goals should be documented before treatment so progress can be evaluated realistically.

Expected results

Clinical studies show that OIT can desensitize some patients, but outcomes vary. Desensitization usually depends on continued exposure and is different from remission after treatment stops.

In the NIH-funded IMPACT trial of children ages 1–3 with peanut allergy, 71% of OIT participants met the study’s desensitization endpoint at the end of treatment, while 21% met its remission endpoint after six months of avoidance. Those trial results should not be used to predict the outcome for an individual child, another food, or a different clinical protocol.

Program video

Oral Immunotherapy Program Overview

A Carefully Measured Process

What Is Oral Immunotherapy?

Measured allergen dosing

OIT introduces a confirmed food allergen in small, measured amounts. Doses are increased only according to a clinician-directed protocol. The goal is desensitization: raising the amount of allergen that causes symptoms while treatment continues.

Program phases

A typical program includes an initial evaluation, confirmation of the food allergy, shared decision-making, supervised dosing or dose increases, daily home dosing, and ongoing maintenance. A food challenge may be recommended when the history and testing do not provide a clear diagnosis, but it is a separate supervised medical procedure.

A plan for treating peanut allergies requires a confirmed diagnosis, clear goals, and steps for safety and follow-up.

Food Allergies Considered

Which Foods Can Be Evaluated for OIT?

Confirmed food allergy

Modena Health may discuss OIT protocols for peanut, tree nuts, milk, egg, sesame, wheat, and other foods when clinically appropriate. Available protocols, ages, foods, and treatment locations vary. The scheduling and clinical teams should confirm that an appropriate program is available before treatment is promised.

Program-specific availability

Skin or blood testing alone does not determine candidacy. The allergist also considers the reaction history, asthma control, gastrointestinal health, current avoidance plan, treatment goals, and the family’s ability to follow a daily protocol.

If you are looking for a food allergy treatment center, use this guide to review the service scope and prepare focused questions before choosing care.

Review the tree nut allergy test guide for symptom patterns, evaluation questions, management options, and reasons to seek specialist care.

A Step-by-Step Care Plan

How Does an OIT Program Work?

Confirm the diagnosis. The allergist reviews the reaction history, prior testing, current avoidance, medications, and any previous emergency treatment. Additional targeted testing or a supervised food challenge may be recommended.
Review candidacy and alternatives. The family discusses expected benefits, known risks, daily responsibilities, other treatment choices, and what success would mean for that patient.
Begin under supervision. Initial dosing and designated dose increases take place in a clinical setting equipped to recognize and treat allergic reactions.
Continue the prescribed home dose. The patient takes only the exact amount and schedule in the written plan and follows the required observation, meal, activity, illness, and hot-water precautions.
Enter maintenance and follow-up. Once the planned maintenance dose is reached, continued dosing and follow-up are usually required to preserve desensitization.

Individual Assessment Matters

Who May Be a Candidate for OIT?

A potential candidate generally has a confirmed IgE-mediated food allergy and a family that can consistently follow daily dosing, monitoring, clinic visits, and emergency instructions.

The allergist will pay particular attention to asthma control; previous anaphylaxis; swallowing difficulty; persistent vomiting, reflux, chest pain, or abdominal pain; a history of eosinophilic esophagitis or another eosinophilic gastrointestinal disorder; and the ability to recognize and treat a reaction. No single skin-test result or blood-test value determines whether OIT is appropriate.

Daily Safety Is Part of Treatment

Home Dosing and Follow-Up

Give only the prescribed dose and never double, halve, skip, or restart a dose unless the written plan or care team specifically directs it.
Follow the protocol’s meal, observation, exercise, heat, and hot-shower restrictions.
Keep prescribed epinephrine immediately available and make sure caregivers know the emergency plan.
Contact the care team for missed doses, illness, fever, an asthma flare, a reaction, or uncertainty about dosing.
Report persistent swallowing trouble, vomiting, reflux, chest pain, or abdominal pain promptly.
Continue all scheduled follow-up visits and prescribed allergen avoidance.

Know When to Get Emergency Help

Urgent Safety Information

Possible anaphylaxis is an emergency. If a dose or exposure is followed by trouble breathing, wheezing, throat tightness, tongue or throat swelling, faintness, confusion, or rapidly developing symptoms in more than one body system, use prescribed epinephrine as directed in the patient’s action plan and call 911. Do not wait for a clinic callback or rely on antihistamines or an inhaler in place of epinephrine.

Patient Questions

Frequently Asked Questions

The goal is to increase the amount of a treated food needed to trigger symptoms while the patient remains on therapy. OIT is intended to provide a margin of protection from some accidental exposures, not unrestricted eating.

No. OIT is generally intended to produce desensitization, and continued maintenance dosing is often required. Patients still need prescribed avoidance, label reading, epinephrine, and an emergency action plan.

Studies show meaningful desensitization for some patients, particularly in research involving peanut, milk, and egg, but results vary substantially. Published averages cannot predict an individual patient’s response.

Reactions may include mouth itching, hives, swelling, abdominal pain, vomiting, wheezing, or anaphylaxis. Persistent gastrointestinal symptoms can require evaluation for an eosinophilic gastrointestinal disorder. The allergist should discuss patient-specific risks before treatment.

The dose-increase phase may take months, and maintenance can continue for years or longer. Timing depends on the allergen, protocol, reactions, missed doses, health changes, and treatment goals.

Follow the written protocol and contact the care team when required. Do not double, halve, or independently restart the dose. Resumption instructions depend on the protocol and the number of missed doses.

No, unless the treating allergist explicitly changes the plan after a supervised assessment. OIT does not remove the need for emergency preparedness.

Protocol availability depends on the food, patient age, health history, location, and clinician assessment. The care team should explain the proposed approach, whether it is FDA-approved or used off-label, and where each stage of care takes place.

Coverage varies by plan and by the services or products involved. Request a benefits review and ask about clinic charges, laboratory testing, supervised visits, and any non-covered treatment materials.

Patient guide

Oral Immunotherapy Treatment Program: decisions, preparation, and safety

Quick answer

OIT is intended to provide protection from a larger amount of accidental exposure than the patient could tolerate before treatment. It is usually described as desensitization, not a cure, and patients continue the avoidance and emergency plan defined by the treating clinician.

Who may want to ask about it

A discussion may be appropriate for a patient with a confirmed IgE-mediated food allergy when the family or adult patient understands the expected benefit, reactions, daily dosing, clinic visits, cost, and lifestyle responsibilities. Readiness and goals matter as much as a positive test.

What the visit or test may answer

The clinician confirms the diagnosis and reaction history, reviews asthma and other health conditions, and may use focused testing or a supervised food challenge when the threshold or diagnosis is uncertain. Candidacy is not determined by an IgE number alone.

How to prepare

Bring reaction and emergency records, testing, current foods avoided and tolerated, all medicines and inhalers, anaphylaxis training questions, school or work needs, exercise schedule, travel plans, eating concerns, insurance details, and the practical barriers that could interrupt daily dosing.

Limits and safety

OIT does not guarantee that a food can be eaten freely, prevent every reaction, replace epinephrine, or treat an active reaction. Protection depends on the program, dose, adherence, cofactors, and individual response.

When symptoms need urgent care

Symptoms of anaphylaxis during dosing require the written emergency plan and immediate care. Persistent swallowing trouble, food sticking, vomiting, chest or abdominal pain, or feeding change should be reported because gastrointestinal inflammation, including eosinophilic esophagitis, may need evaluation.

Alternatives to discuss

Alternatives include continued avoidance with updated emergency planning, diagnostic clarification through a supervised food challenge, FDA-approved peanut OIT when appropriate, a clinic-specific OIT protocol, or biologic therapy for a current approved food-allergy indication.

A useful next step

Ask which food and product are proposed, whether the treatment is FDA-approved or clinic-protocol care, the target outcome, visit schedule, home-dose rules, reaction rate, cofactor restrictions, stopping criteria, cost, and what daily life looks like after maintenance.

Set the Right Goal

Desensitization, remission, and why OIT is not called a cure

Desensitization means a patient can tolerate more of the food while taking regular treatment than before OIT. This can create a buffer against accidental exposure and reduce food-allergy anxiety for some families. The threshold and meaningful benefit differ, so the consultation should define whether the goal is protection from traces, a particular serving, or another measurable outcome.

Some patients may retain protection after a period without daily treatment, sometimes called sustained unresponsiveness or remission, but this is less predictable and depends on the food, age, protocol, duration, and individual response. Most patients should expect ongoing dosing unless the treating team conducts a structured assessment. OIT does not erase the diagnosis or make uncontrolled home testing safe.

Confirm the Food Allergy

History, testing, and food challenges before treatment

OIT should target a real IgE-mediated food allergy. Skin tests and blood tests estimate sensitization and probability but do not show the exact dose a person can eat safely. A convincing reaction history may establish the diagnosis, while an uncertain or remote history may require a supervised oral food challenge before committing to years of treatment.

The evaluation also covers asthma control, prior anaphylaxis, eosinophilic or swallowing disease, other medical conditions, medicines, feeding concerns, pregnancy when relevant, and the patient’s ability to communicate symptoms. Families should discuss whether a child can cooperate with daily dosing and whether the household can provide consistent supervision without creating conflict or unsafe pressure around food.

Understand Products and Protocols

FDA-approved peanut OIT and clinic-based food OIT

PALFORZIA is an FDA-approved peanut allergen powder. Current FDA information permits initial dose escalation in patients ages one through seventeen with a confirmed peanut allergy, with up-dosing and maintenance continued from age one and older. It is used with peanut avoidance and is not emergency treatment. The label, risk program requirements, and current availability should be confirmed during consultation.

Clinics may also offer food OIT using measured food products or protocols for peanut and other foods. These programs are not the same as an FDA-approved product, and evidence, preparation, dosing, coverage, and consent can differ. The team should name what is being used, explain the evidence for that food and age, and separate established facts from protocol-specific practice.

Move Through the Program

Initial escalation, up-dosing, and daily maintenance

Programs generally begin with supervised dosing, followed by clinic up-dosing visits separated by daily home doses at the current level. The amount increases only when the clinical team determines that the previous dose is tolerated and the patient is well enough to proceed. Reaching maintenance changes the schedule but does not end daily responsibility.

Each home dose must be measured and given exactly as instructed. The written plan should address timing with food, post-dose observation, activity restriction, bathing or heat, illness, fever, asthma symptoms, sleep loss, menstruation when relevant, alcohol for adults, missed doses, travel, and accidental exposure. These factors can lower the reaction threshold even when a dose was previously tolerated.

Prepare for Reactions

Common symptoms, anaphylaxis, and gastrointestinal concerns

Mouth or throat itching, hives, abdominal discomfort, vomiting, cough, and wheeze can occur during OIT, and systemic reactions including anaphylaxis are possible. Families need epinephrine available, should know the written criteria for use, and should understand when to hold a dose and contact the program. Antihistamines can change symptoms but do not replace epinephrine for anaphylaxis.

Recurring abdominal pain, vomiting, reduced appetite, feeding difficulty, trouble swallowing, food sticking, or chest discomfort deserves review rather than being accepted as the price of treatment. OIT can be associated with eosinophilic gastrointestinal disease in some patients. The team should explain how symptoms are tracked, what prompts a pause, and when another evaluation is needed.

Compare All Reasonable Paths

Avoidance, OIT, biologics, and quality-of-life tradeoffs

Careful avoidance with label reading, cross-contact planning, epinephrine access, and updated school or travel plans remains a valid pathway. OIT adds daily exposure and reaction risk in exchange for a higher threshold while therapy continues. Some families value that protection; others find the dosing routine, food aversion, clinic time, anxiety, or cost too burdensome.

In 2024 the FDA approved omalizumab for certain adults and children age one and older with IgE-mediated food allergy to reduce reactions after accidental exposure to one or more foods. It does not allow free eating or treat an active reaction. The biologics guide explains that pathway. Shared decision-making should compare the desired outcome, evidence, burden, uncertainty, and what happens if treatment stops.

Compare the Options

Food-allergy management pathways compared

These options can have different goals and may sometimes be combined under specialist care.

Food-allergy management pathways compared
Pathway	Primary goal	Ongoing responsibilities
Avoidance and emergency planning	Prevent exposure and treat accidental reactions promptly	Labels, cross-contact, epinephrine, training, and updated school, work, and travel plans
Oral food challenge	Confirm diagnosis, threshold, or possible resolution under supervision	Preparation for a one-day procedure and a clear plan based on the result
Food OIT	Raise the reaction threshold while regular dosing continues	Supervised escalation, daily dosing, cofactor rules, reactions, epinephrine, and follow-up
Omalizumab for food allergy	Reduce reaction risk after accidental exposure for an approved population	Avoidance continues; injections, authorization, safety, and response review remain necessary

Patient questions

Frequently asked questions about Oral Immunotherapy Treatment Program

What is oral immunotherapy for food allergy?

OIT gives carefully measured amounts of a confirmed food allergen through supervised escalation and regular home dosing to raise the reaction threshold while treatment continues.

Does OIT cure food allergy?

No. OIT usually produces desensitization rather than a guaranteed permanent cure. Patients continue the avoidance and emergency plan defined by their treatment program.

Who may be a candidate for food OIT?

Candidacy requires a confirmed IgE-mediated food allergy, acceptable medical safety, a realistic treatment goal, and the ability to complete daily dosing, clinic visits, precautions, and emergency preparation.

What ages can use FDA-approved peanut OIT?

Current FDA information allows PALFORZIA initial dose escalation for ages one through seventeen and continuation of up-dosing and maintenance from age one and older. The clinician must confirm current labeling and individual candidacy.

Can OIT treat foods other than peanut?

Some specialty programs use clinic protocols for other foods, but these are not the same as an FDA-approved food-allergy product. Evidence, preparation, dose, consent, and coverage should be discussed clearly.

How long does food OIT take?

Up-dosing commonly takes months and maintenance may continue for years or indefinitely. The exact schedule depends on the program, reactions, illness, missed doses, and treatment goal.

Can I exercise after an OIT dose?

Exercise, heat, illness, sleep loss, and other cofactors can increase reaction risk. Follow the program’s exact timing restrictions and contact the team when circumstances change.

What should happen when an OIT dose is missed?

Instructions depend on the length of the gap and the protocol. Contact the program before restarting after a meaningful interruption and never double a dose.

Can OIT cause anaphylaxis?

Yes. Reactions including anaphylaxis are possible, so epinephrine, training, observation, written dose rules, and rapid communication with the program are essential.

Why do swallowing or stomach symptoms matter during OIT?

Persistent pain, vomiting, feeding change, trouble swallowing, or food sticking can signal a gastrointestinal problem including eosinophilic inflammation and should be reported promptly.

How is OIT different from an oral food challenge?

A food challenge is a supervised diagnostic procedure that answers whether or how much a food is tolerated. OIT is ongoing treatment with repeated dosing intended to change the threshold.

How is OIT different from omalizumab for food allergy?

OIT repeatedly doses the food; omalizumab is a biologic injection approved to reduce reactions after accidental exposure in certain patients. Neither replaces avoidance or emergency treatment.

Choose the right next step

Contact Modena Health with a specific care question, or review clinic information before planning a visit.

Contact Modena Health Find a Location

Live Well

Request a consultation with our team.

Full name

Phone number

Email address

Procedure of interest

Best time to reach you

Preferred location

How can we assist you?

Call (858) 260-2977

Oral Immunotherapy Treatment Program